(Alliance News) - Proteome Sciences PLC on Monday launched SysQuant SCP, a commercial service for single cell proteomics using isobaric labelling reagents.
Proteome is a London-based protein-focused drug development services provider. Shares in the firm were up 13% at 7.15 pence each in London on Monday morning.
SysQuant and TMT MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity.
SysQuant can identify more than 1,000 proteins in each study of 576 single cells. By contrast, more traditional approaches measure only a few tens of proteins on each cell.
According to Proteome, data from the SysQuant pipeline will "greatly improve" our understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy.
In turn, this will help to offer new therapeutic and diagnostic targets for personalised medicine.
"We are pleased to be one of the first CROs providing single cell proteomics to our customers. The launch of SysQuant SCP is part of our growth strategy along with the opening of a US facility in San Diego," said Chief Executive Officer Mariola Soehngen.
"We believe that broadening our range of services and increasing capacity are essential as the wider pharmaceutical industry increasingly recognises the need to study changes in protein expression and function to further advance and accelerate the drug development process."
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Proteome (PRM)